Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147
In development [GID-TA10343] Expected publication date: TBC
Search results
527 results
-
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
In development [GID-TA10599] Expected publication date: TBC
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
In development [GID-TA10221] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: 24 February 2021
-
Atrial fibrillation - vernakalant [ID454]
In development [GID-TAG428] Expected publication date: 17 February 2021
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: TBC
-
Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]
In development [GID-TA10595] Expected publication date: TBC
-
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]
In development [GID-TA10474] Expected publication date: TBC
-
Pembrolizumab for previously treated endometrial cancer [ID1205]
In development [GID-TA10243] Expected publication date: TBC
-
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]
In development [GID-TA10569] Expected publication date: TBC
-
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
In development [GID-TA10483] Expected publication date: TBC
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]
In development [GID-TA10119] Expected publication date: TBC
-
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
In development [GID-TA10780] Expected publication date: TBC
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]
In development [GID-TA10314] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma ID3856
In development [GID-TA10836] Expected publication date: TBC
-
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535
In development [GID-TA10412] Expected publication date: TBC
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
In development [GID-TA10768] Expected publication date: TBC
-
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]
In development [GID-TA10442] Expected publication date: TBC
-
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404
In development [GID-TA10327] Expected publication date: TBC